Infection alone does not seem to increase the likelihood of another early delivery
For pregnant individuals already carrying the weight of a prior preterm birth, a new study from UTHealth Houston offers a measured reassurance: Mycoplasma genitalium, a stealthy and difficult-to-detect sexually transmitted bacterium long suspected of compounding pregnancy risk, does not appear to drive recurrent early delivery. Published in The American Journal of Obstetrics and Gynecology, the finding invites clinicians and patients alike to reconsider what they fear — and why — in the complex landscape of high-risk pregnancy.
- Preterm birth remains one of the leading causes of infant death, and any suspected trigger demands serious scrutiny — Mycoplasma genitalium had been on that list.
- The bacterium is unusually elusive: it lacks a cell wall, spreads without symptoms, and has been linked to inflammation and increased HIV risk, making its potential role in pregnancy complications feel plausible and alarming.
- Nearly 500 high-risk pregnant individuals were tested in a first-of-its-kind prospective study, and 12% carried the infection — a rate notably higher among those with prior preterm births.
- Yet when researchers tracked outcomes forward, the infection did not predict another early delivery or second-trimester loss, suggesting its presence and its danger are not the same thing.
- The study lands as a corrective against overcaution: while Mycoplasma genitalium's antibiotic resistance and HIV links remain real public health concerns, its threat to recurrent pregnancy may have been overstated.
Researchers at UTHealth Houston have published a finding that may ease one source of anxiety for pregnant individuals with a history of early delivery: Mycoplasma genitalium, a sexually transmitted bacterium previously suspected of triggering recurrent preterm birth, does not appear to do so.
The bacterium is an unusual one — so small it lacks the cell wall common to most bacteria, making it hard to detect and treat. It often causes no symptoms, yet has been linked to genital inflammation and increased susceptibility to HIV, giving researchers reason to wonder whether it might also complicate pregnancy. Preterm birth, defined as delivery before 37 weeks, is a leading cause of infant illness and death, making every potential risk factor worth examining.
The study followed nearly 500 pregnant individuals — all with a history of preterm birth or related complications — from mid-2023 through late 2025. Early vaginal swab testing revealed that 12 percent carried the infection, with notably higher rates among those who had already delivered early. But when researchers tracked what followed, the presence of the bacterium did not increase the likelihood of another spontaneous preterm birth, nor did it raise the risk of second-trimester loss from cervical insufficiency.
Dr. Irene Stafford, the study's lead author, noted that the infection may carry greater risk during a first exposure, before the immune system has learned to respond, rather than in subsequent pregnancies. The team is careful to acknowledge that preterm birth has many contributing factors, and no single study resolves them all.
Still, the work offers something rare in high-risk obstetric care: data-grounded reassurance. For a bacterium growing increasingly resistant to antibiotics, knowing where its threat is real — and where it may have been overstated — matters both for individual patients and for broader public health decisions around screening and treatment.
Researchers at UTHealth Houston have found something reassuring for pregnant women with a history of early delivery: a common sexually transmitted infection long suspected of triggering recurrent preterm birth does not, in fact, appear to do so. The finding, published in The American Journal of Obstetrics and Gynecology, challenges earlier concerns about Mycoplasma genitalium and offers clarity to clinicians and patients navigating high-risk pregnancies.
Mycoplasma genitalium is a bacterium so small it lacks the cell wall that most bacteria possess, making it difficult to detect and treat. It spreads through sexual contact and often causes no symptoms at all, though some people experience inflammation or irritation of the urethra or reproductive tract. Because the infection is linked to inflammation and has been associated with increased risk of acquiring HIV, researchers wondered whether it might also contribute to pregnancy complications. Preterm birth—delivery before 37 weeks—remains a leading cause of infant illness and death, making any potential risk factor worth investigating.
The study enrolled nearly 500 pregnant individuals between July 2023 and December 2025, all of whom had experienced either a prior preterm birth or related complications. Early in their pregnancies, participants underwent vaginal swab testing for Mycoplasma genitalium using an FDA-cleared test. The results showed that 12 percent tested positive for the infection. Notably, the bacterium was significantly more common among those who had already had a preterm birth, suggesting some association with past complications.
But the critical finding came when researchers tracked what happened next. Among those who tested positive for Mycoplasma genitalium, the infection did not increase the likelihood of another spontaneous preterm birth. The study also examined whether the infection raised the risk of second-trimester loss caused by cervical insufficiency—another pregnancy complication—and found no elevated risk there either. The data suggested that while the bacterium might be present more often in women with a history of early delivery, its presence did not predict whether they would deliver early again.
Dr. Irene Stafford, the study's first author and an assistant professor of obstetrics, gynecology, and reproductive sciences at UTHealth Houston's McGovern Medical School, emphasized the practical importance of the finding. For individuals already at high risk of preterm birth, she noted, Mycoplasma genitalium infection alone does not appear to increase the chances of another early delivery. The researchers suggest that the infection may pose greater risk during a first exposure, before the body has mounted an immune response, rather than in subsequent pregnancies where immunity may already be present.
The work represents the first prospective study of its kind, following pregnant individuals forward in time rather than looking backward at medical records. Yet the researchers are careful not to overstate their conclusions. Preterm birth is influenced by many factors—maternal age, stress, infection, inflammation, genetic predisposition, and more—and no single study can account for all of them. More research will be needed to fully understand Mycoplasma genitalium's role across different populations and pregnancy scenarios.
Still, in a field where uncertainty often drives unnecessary treatment, the study offers something valuable: reassurance grounded in data. For women already managing the anxiety of high-risk pregnancy, knowing that one particular infection is not driving their risk may help guide decisions about screening and treatment. And for a bacterium increasingly resistant to antibiotics, that distinction matters. The findings do not suggest complacency—Mycoplasma genitalium's links to HIV acquisition and its growing resistance to available drugs remain public health concerns. But they do suggest that the infection's threat to pregnancy may have been overstated, at least in the specific scenario of recurrent preterm birth.
Citas Notables
For individuals already at high risk of preterm birth, Mycoplasma genitalium infection alone does not seem to increase the likelihood of another early delivery.— Dr. Irene Stafford, assistant professor of obstetrics, gynecology, and reproductive sciences at UTHealth Houston
La Conversación del Hearth Otra perspectiva de la historia
Why did researchers suspect this particular bacterium in the first place?
Because it causes inflammation, and inflammation is a known pathway to preterm labor. When you have a sexually transmitted infection that triggers an inflammatory response, it's reasonable to ask whether that inflammation might destabilize a pregnancy. The earlier studies hinting at a connection made the question feel urgent.
But this study found no connection in recurrent cases. Does that mean the earlier research was wrong?
Not necessarily. Those earlier studies were limited in scope. This one is the first to follow pregnant women forward prospectively—to actually watch what happens to them. It's possible the earlier work was picking up on something real but incomplete, or studying different populations where the risk was different.
The study notes the infection was more common in women who'd already had a preterm birth. Isn't that suspicious?
It is, and that's what makes the finding so interesting. The association is there, but it doesn't predict future outcomes. It suggests the infection may be a marker of something else—maybe past inflammation, maybe a different underlying vulnerability—rather than a driver of recurrent problems.
What about women having their first pregnancy? Could the risk be different there?
That's exactly what the researchers are saying. They suspect the real danger window might be during initial infection, before immunity develops. Once you've been exposed and your immune system has responded, subsequent pregnancies might be protected. But that's speculation at this point. It needs testing.
So should doctors stop screening for this infection in pregnant women?
The study doesn't say that. It says screening shouldn't drive treatment decisions based on recurrent preterm birth risk alone. But the infection is still linked to other concerns—HIV acquisition, for instance. The question of whether to screen depends on what you're trying to prevent and what you'll do with the information.
What's the antimicrobial resistance angle you mentioned?
Mycoplasma genitalium is developing resistance to the antibiotics we use to treat it. If we're treating every positive case aggressively, we're accelerating that resistance. A study showing that not every positive case needs treatment—especially in certain scenarios—actually helps preserve the effectiveness of the drugs we do have.